Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies

Smita Vaidya, David Partlow, Titus Barnes, Kristene Gugliuzza

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

BACKGROUND. This study tests a hypothesis that pretransplant concentration of soluble CD30 (sCD30) is a better predictor of posttransplant development of donor-specific HLA antibodies (DSA) and acute vascular rejection (AVR) than panel reactive HLA antibodies (PRA). METHODS. Pretransplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin-inhibitor based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven AVR episodes within first 6 months of the transplant. Posttransplant sera of patients with or without AVR were tested for the presence of DSA. RESULTS. AVR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared to those patients negative for both tests (36% versus 5%, p=0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% versus 5%, p=0.04). Of the 18 patients with AVR, 14 were positive for sCD30, and 13 of them (93%) developed DSA posttransplant (p=0.001) Nineteen patients without AVR were tested for DSA and sCD30 concentrations. Only two of these 19 patients were positive for sCD30 and DSA. AVR was strongly associated with the patients tested positive for both the tests: DSA and sCD30 (p=0.00007). Furthermore, patients with AVR are more likely to produce DSA than those without AVR (p=0.02). CONCLUSION. These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.

Original languageEnglish (US)
Pages (from-to)1606-1609
Number of pages4
JournalTransplantation
Volume82
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

Blood Vessels
Tissue Donors
Antibodies
Immunosuppressive Agents
Serum
Transplants
Biopsy

Keywords

  • Acute rejection
  • Acute vascular rejection
  • Flow cytometry crossmatches
  • Panel reactive antibodies
  • Soluble CD30

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. / Vaidya, Smita; Partlow, David; Barnes, Titus; Gugliuzza, Kristene.

In: Transplantation, Vol. 82, No. 12, 12.2006, p. 1606-1609.

Research output: Contribution to journalArticle

@article{26d9d4f4b65c49b0b75547636e144d50,
title = "Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies",
abstract = "BACKGROUND. This study tests a hypothesis that pretransplant concentration of soluble CD30 (sCD30) is a better predictor of posttransplant development of donor-specific HLA antibodies (DSA) and acute vascular rejection (AVR) than panel reactive HLA antibodies (PRA). METHODS. Pretransplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin-inhibitor based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven AVR episodes within first 6 months of the transplant. Posttransplant sera of patients with or without AVR were tested for the presence of DSA. RESULTS. AVR rate was 16{\%} (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared to those patients negative for both tests (36{\%} versus 5{\%}, p=0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21{\%} versus 5{\%}, p=0.04). Of the 18 patients with AVR, 14 were positive for sCD30, and 13 of them (93{\%}) developed DSA posttransplant (p=0.001) Nineteen patients without AVR were tested for DSA and sCD30 concentrations. Only two of these 19 patients were positive for sCD30 and DSA. AVR was strongly associated with the patients tested positive for both the tests: DSA and sCD30 (p=0.00007). Furthermore, patients with AVR are more likely to produce DSA than those without AVR (p=0.02). CONCLUSION. These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.",
keywords = "Acute rejection, Acute vascular rejection, Flow cytometry crossmatches, Panel reactive antibodies, Soluble CD30",
author = "Smita Vaidya and David Partlow and Titus Barnes and Kristene Gugliuzza",
year = "2006",
month = "12",
doi = "10.1097/01.tp.0000248530.66421.50",
language = "English (US)",
volume = "82",
pages = "1606--1609",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies

AU - Vaidya, Smita

AU - Partlow, David

AU - Barnes, Titus

AU - Gugliuzza, Kristene

PY - 2006/12

Y1 - 2006/12

N2 - BACKGROUND. This study tests a hypothesis that pretransplant concentration of soluble CD30 (sCD30) is a better predictor of posttransplant development of donor-specific HLA antibodies (DSA) and acute vascular rejection (AVR) than panel reactive HLA antibodies (PRA). METHODS. Pretransplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin-inhibitor based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven AVR episodes within first 6 months of the transplant. Posttransplant sera of patients with or without AVR were tested for the presence of DSA. RESULTS. AVR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared to those patients negative for both tests (36% versus 5%, p=0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% versus 5%, p=0.04). Of the 18 patients with AVR, 14 were positive for sCD30, and 13 of them (93%) developed DSA posttransplant (p=0.001) Nineteen patients without AVR were tested for DSA and sCD30 concentrations. Only two of these 19 patients were positive for sCD30 and DSA. AVR was strongly associated with the patients tested positive for both the tests: DSA and sCD30 (p=0.00007). Furthermore, patients with AVR are more likely to produce DSA than those without AVR (p=0.02). CONCLUSION. These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.

AB - BACKGROUND. This study tests a hypothesis that pretransplant concentration of soluble CD30 (sCD30) is a better predictor of posttransplant development of donor-specific HLA antibodies (DSA) and acute vascular rejection (AVR) than panel reactive HLA antibodies (PRA). METHODS. Pretransplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin-inhibitor based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven AVR episodes within first 6 months of the transplant. Posttransplant sera of patients with or without AVR were tested for the presence of DSA. RESULTS. AVR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared to those patients negative for both tests (36% versus 5%, p=0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% versus 5%, p=0.04). Of the 18 patients with AVR, 14 were positive for sCD30, and 13 of them (93%) developed DSA posttransplant (p=0.001) Nineteen patients without AVR were tested for DSA and sCD30 concentrations. Only two of these 19 patients were positive for sCD30 and DSA. AVR was strongly associated with the patients tested positive for both the tests: DSA and sCD30 (p=0.00007). Furthermore, patients with AVR are more likely to produce DSA than those without AVR (p=0.02). CONCLUSION. These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.

KW - Acute rejection

KW - Acute vascular rejection

KW - Flow cytometry crossmatches

KW - Panel reactive antibodies

KW - Soluble CD30

UR - http://www.scopus.com/inward/record.url?scp=33845939480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845939480&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000248530.66421.50

DO - 10.1097/01.tp.0000248530.66421.50

M3 - Article

VL - 82

SP - 1606

EP - 1609

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -